Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Meiji/KM Biologics Change Target Strain of Investigational COVID Jab
April 21, 2025
- Eye Drop for Myopia Control Enters PII Study in Japan: Rohto
April 21, 2025
- UCB Japan Launches IV Form of Epilepsy Med Briviact
April 18, 2025
- Investments Follow Where Innovation Is Valued, Says Novartis Japan Chief
April 18, 2025
- Gilead Shelves Sunlenca’s PrEP Program in Japan as Coverage Issue Weighs
April 17, 2025
- Gilead Japan Revving Up Oncology Drive with Trodelvy, CAR-T as Legs of Growth
April 17, 2025
- Amgen Rolls Out Imdelltra for SCLC in Japan
April 17, 2025
- Eisai’s Alzheimer’s Drug Leqembi Now Approved in Europe
April 16, 2025
- Marubeni Sees Drug Biz Opportunities in Global Markets with Supply-Demand Gaps
April 16, 2025
- Asahi Kasei on Hunt for M&A and Licensing Deals to Bolster Pharma Biz
April 15, 2025
- Welcia, Tsuruha to Merge in December 2025 to Create Top Drugstore Group
April 15, 2025
- AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
- Servier Poised to Double Japan Workforce over Next 3 Years: CEO, Local Chief
April 14, 2025
- RaQualia Ends Tamibarotene License Pact with Syros
April 14, 2025
- Japan Biotechs to Be Hit Hard by TSE Growth Market Reform, 26 Firms Fail to Reach Proposed Threshold
April 11, 2025
- Kaken Bags Japan Commercial Rights to KalVista’s HAE Drug
April 10, 2025
- KM Biologic President to Be Promoted to Meiji Group’s Pharma Chief
April 9, 2025
- Daiichi Sankyo’s Datroway Approved in Europe for Breast Cancer
April 9, 2025
- JCR to Fuel Licensing of J-Brain Cargo, Invest in Global R&D: President
April 9, 2025
- Japan Infectious Disease Market Projected to Drop to 771.8 Billion Yen in 2033: Fuji Keizai
April 9, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…